Intranasal Mosaic H1N1 Live Attenuated Influenza Vaccine Elicits Broad Cross‐Reactive Immunity and Protection Against Group 1 and 2 Influenza A Viruses
Ximeng Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuelong Shu(Sun Yat-sen University), Yuhang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Tian Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuejie Liu(Shenzhen University), Xue Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Li(Jiangxi Academy of Agricultural Sciences), Chen Chen(Nanjing Agricultural University), Liangliang Wang(National Institutes for Food and Drug Control), Zhuolin Yang(Shenzhen University), Rui Ma(Jiangsu Normal University), Jian Lü(National Institute for Viral Disease Control and Prevention), Yi‐Hao Chen(National Defense Medical Center), Yuhang Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Wang Pang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Chen(Fujian Normal University)
Cited by 1
Related Papers
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis
|Journal of Infection|2020|1.2k
Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China
|New England Journal of Medicine|2013|698
Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study
|The Lancet|2014|663
Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
|Nature Communications|2014|422